Cargando…
Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
BACKGROUND: Data for bronchodilator deposition via nebulizers and dry powder inhalers (DPIs) in the respiratory tract of patients with chronic obstructive pulmonary disease (COPD) are limited. We used functional respiratory imaging (FRI) to determine deposition patterns for revefenacin solution via...
Autores principales: | Crater, Glenn D., Johnson, Karmon, Ward, Jonathan, Backer, Jan De |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894616/ https://www.ncbi.nlm.nih.gov/pubmed/35234085 http://dx.doi.org/10.1177/17534666221077561 |
Ejemplares similares
-
Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*
por: Colthorpe, Paul, et al.
Publicado: (2013) -
Revefenacin, a once-daily, long-acting muscarinic antagonist, for
nebulized maintenance therapy in patients with chronic obstructive pulmonary
disease
por: Hvisdas, Christopher
Publicado: (2021) -
Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization
por: Akkerman-Nijland, A. M., et al.
Publicado: (2020) -
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020) -
Inhalation of Nebulized Fluids
Publicado: (1866)